Clinical Trial Update: To Evaluate 24-hr Glucose After OD vs BD AZD1656 [Phase 1]

View source ↗

Summary

Phase 1 study comparing 24-hour glucose responses after once-daily versus twice-daily dosing of AZD1656 in adults with Type 2 diabetes mellitus; the trial statu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• AZD1656

Snippet

Sponsor: AstraZeneca | Conditions: Type II Diabetes | Phase 1 | Status: COMPLETED